Premium Nahrungsergänzungsmittel | artgerecht

Urokinase – Mechanism, Uses & Side Effects

Urokinase is a naturally occurring enzyme and thrombolytic agent that dissolves blood clots. It is used medically to treat dangerous thromboses and embolisms.

Regular tips about health Regular tips about health

Things worth knowing about "Urokinase"

Urokinase is a naturally occurring enzyme and thrombolytic agent that dissolves blood clots. It is used medically to treat dangerous thromboses and embolisms.

What is Urokinase?

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a naturally occurring enzyme found in various tissues and in urine. It belongs to the class of thrombolytics (clot-dissolving agents) and is used clinically to dissolve dangerous blood clots within the body. As a pharmaceutical agent, urokinase is derived from human urine or produced through biotechnological processes.

Mechanism of Action

Urokinase works by converting the endogenous protein plasminogen into its active form, plasmin. Plasmin is an enzyme that breaks down fibrin, the main structural component of blood clots. Through this mechanism, existing clots are dissolved and blood flow is restored in occluded vessels.

Urokinase binds to specific cell surface receptors (uPA receptor, uPAR).
It directly and efficiently converts plasminogen to plasmin.
Plasmin cleaves fibrin, thereby dissolving the thrombus.
Its effects can be both local (at the clot site) and systemic.

Medical Indications

Urokinase is used in clinical medicine for various indications where blood clots cause life-threatening conditions:

Pulmonary embolism: Dissolution of clots in the pulmonary vessels in hemodynamically unstable patients.
Deep vein thrombosis (DVT): Treatment of extensive thrombosis in the deep veins of the legs.
Arterial occlusions: Restoration of blood flow in acute arterial occlusions affecting limbs or organs.
Catheter occlusion: Clearing of blocked central venous catheters or dialysis catheters.
Myocardial infarction: Historically used to dissolve coronary thrombi, largely replaced by newer thrombolytics today.

Dosage and Administration

Urokinase is administered exclusively intravenously (into a vein) or locally via catheter directly into the affected vessel. The exact dosage depends on the indication, body weight, and clinical condition of the patient, and is always determined by qualified medical personnel.

For pulmonary embolism: Typically as a bolus dose followed by a continuous infusion over several hours.
For catheter occlusion: Local administration at significantly lower doses.
Treatment is always performed under intensive medical monitoring.

Side Effects and Risks

Since urokinase affects blood coagulation, the most important risk is bleeding complications. These can range from minor bleeds to life-threatening internal hemorrhages.

Common: Bleeding at puncture sites, hematomas.
Serious: Intracranial hemorrhage (in the brain), gastrointestinal bleeding.
Allergic reactions: Rare but possible (skin rash, fever, chills).
Embolization: Dislodgement of fragments from the dissolving clot.

Contraindications

Urokinase must not be used in patients with:

Active bleeding or significantly increased bleeding risk.
Recent surgery or trauma.
History of stroke (especially hemorrhagic stroke).
Severe uncontrolled hypertension (high blood pressure).
Pregnancy (relative contraindication).

Relevance in Modern Medicine

Urokinase was one of the first thrombolytic agents and revolutionized the treatment of life-threatening vascular occlusions. In modern medicine, it is complemented or partially replaced by newer thrombolytics such as alteplase (rt-PA). Nevertheless, urokinase remains an important tool, particularly for local catheter-directed thrombolysis and the treatment of catheter occlusions.

References

Konstantinides S.V. et al. -- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2020; 41(4): 543-603.
Lijnen H.R. -- Pleiotropic functions of plasminogen activator inhibitor-1. Journal of Thrombosis and Haemostasis, 2005; 3(1): 35-45.
Ouriel K. -- Comparison of surgical and thrombolytic treatment of peripheral arterial occlusive disease. European Journal of Radiology, 1996; 23(1): 7-10.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.